Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Ionis Pharmaceuticals Inc (IONS)  
$41.59 0.25 (0.6%) as of 4:30 Fri 4/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 143,470,000
Market Cap: 5.97(B)
Last Volume: 998,037 Avg Vol: 995,252
52 Week Range: $34.73 - $53.55
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  292
Guru Rank Value     : 4.1
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Ionis Pharmaceuticals is engaged in RNA-targeted therapeuty. Co.'s commercial products are SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA injection for intrathecal use is a survival motor neuron-2 directed antisense medicine indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. TEGSEDI injection is an RNA-targeted medicine indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 53,575 463,764 501,366 628,895
Total Sell Value $2,637,244 $23,296,725 $24,905,844 $29,967,993
Total People Sold 10 12 13 13
Total Sell Transactions 12 43 51 77
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 1118
  Page 1 of 45  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Baroldi Joseph EVP, Chief Business Officer   •       –      –    2024-04-16 4 S $41.60 $166,641 D/D (4,006) 19,631 -1%     
   Birchler Brian EVP, Corp and Development Ops   •       –      –    2024-04-16 4 S $41.66 $37,698 D/D (905) 46,156 -1%     
   Baroldi Joseph EVP, Chief Business Officer   •       –      –    2024-04-15 4 OE $0.00 $0 D/D 10,838 23,637     -
   Birchler Brian EVP, Corp and Development Ops   •       –      –    2024-04-15 4 OE $0.00 $0 D/D 1,875 47,061     -
   Bennett C Frank Officer Level 14   •       –      –    2024-02-29 4 A $34.43 $13,185 D/D 383 79,462     -
   Birchler Brian Vice President Level 14   •       –      –    2024-02-29 4 A $34.43 $20,793 D/D 604 45,186     -
   Monia Brett P CEO Level 15   •       •      –    2024-02-29 4 A $34.43 $18,521 D/D 538 174,289     -
   Geary Richard S Officer Level 14   •       –      –    2024-02-29 4 A $34.43 $20,793 D/D 604 87,938     -
   Swayze Eric Officer Level 14   •       –      –    2024-02-29 4 A $34.43 $20,827 D/D 605 34,929     -
   Jenne Kyle EVP, Chf GL Pdt Str OfcrOffice   •       –      –    2024-02-26 3 IO $0.00 $0 D/D 0 1,989 -9%     
   Monia Brett P Chief Executive Officer   •       •      –    2024-02-16 4 S $44.49 $17,219 D/D (387) 173,751 6%     
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2024-02-02 4 S $49.59 $102,701 D/D (2,071) 49,812 16%     
   Monia Brett P Chief Executive Officer   •       •      –    2024-02-02 4 S $49.37 $1,160,303 D/D (23,501) 174,138 16%     
   Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc   •       –      –    2024-02-02 4 S $49.60 $105,404 D/D (2,125) 35,825 16%     
   Swayze Eric EVP Research   •       –      –    2024-02-02 4 S $49.56 $94,513 D/D (1,907) 34,324 16%     
   Geary Richard S EVP, Chief Development Officer   •       –      –    2024-02-02 4 S $50.04 $98,135 D/D (1,961) 87,334 16%     
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2024-02-02 4 S $49.67 $97,410 D/D (1,961) 48,661 16%     
   Hougen Elizabeth L EVP, Finance & CFO   •       –      –    2024-02-02 4 S $49.54 $105,272 D/D (2,125) 92,905 16%     
   Bennett C Frank EVP, Chief Scientific Officer   •       –      –    2024-02-02 4 S $49.52 $91,752 D/D (1,853) 79,079 16%     
   Schneider Eugene EVP, Chf Clinical Develop Ofcr   •       –      –    2024-02-01 4 A $0.00 $0 D/D 4,033 51,883     -
   Monia Brett P Chief Executive Officer   •       •      –    2024-02-01 4 A $0.00 $0 D/D 45,788 197,639     -
   Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc   •       –      –    2024-02-01 4 A $0.00 $0 D/D 4,140 37,950     -
   Swayze Eric EVP Research   •       –      –    2024-02-01 4 A $0.00 $0 D/D 3,715 36,231     -
   Geary Richard S EVP, Chief Development Officer   •       –      –    2024-02-01 4 A $0.00 $0 D/D 3,820 89,295     -
   Oneil Patrick R. EVP CLO & General Counsel   •       –      –    2024-02-01 4 A $0.00 $0 D/D 3,820 50,622     -
  1118 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 45
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us